MX2023014457A - Peptidos antigenicos para la prevencion y el tratamiento del cancer. - Google Patents
Peptidos antigenicos para la prevencion y el tratamiento del cancer.Info
- Publication number
- MX2023014457A MX2023014457A MX2023014457A MX2023014457A MX2023014457A MX 2023014457 A MX2023014457 A MX 2023014457A MX 2023014457 A MX2023014457 A MX 2023014457A MX 2023014457 A MX2023014457 A MX 2023014457A MX 2023014457 A MX2023014457 A MX 2023014457A
- Authority
- MX
- Mexico
- Prior art keywords
- antigenic peptides
- present
- cancer
- prevention
- treatment
- Prior art date
Links
- 230000000890 antigenic effect Effects 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001119—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a inmunoterapia basada en antígenos, en particular inmunoterapia contra el cáncer. En particular, la presente invención proporciona péptidos antigénicos, que son distintos de, pero tienen similitud de aminoácidos con, fragmentos de antígenos tumorales humanos. La presente invención proporciona además compuestos inmunogénicos, nanopartículas, células y composiciones farmacéuticas que comprenden dichos péptidos antigénicos, y ácidos nucleicos que codifican dichos péptidos antigénicos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18305444 | 2018-04-11 | ||
EP2018077512 | 2018-10-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023014457A true MX2023014457A (es) | 2023-12-15 |
Family
ID=66092357
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020010701A MX2020010701A (es) | 2018-04-11 | 2019-04-11 | Péptidos antigénicos para la prevención y el tratamiento del cáncer. |
MX2023014457A MX2023014457A (es) | 2018-04-11 | 2020-10-09 | Peptidos antigenicos para la prevencion y el tratamiento del cancer. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020010701A MX2020010701A (es) | 2018-04-11 | 2019-04-11 | Péptidos antigénicos para la prevención y el tratamiento del cáncer. |
Country Status (17)
Country | Link |
---|---|
EP (2) | EP4169528A1 (es) |
JP (2) | JP7384819B2 (es) |
CN (1) | CN112118863A (es) |
AU (1) | AU2019253217A1 (es) |
BR (1) | BR112020020780A2 (es) |
CA (1) | CA3094262A1 (es) |
DK (1) | DK3773689T3 (es) |
ES (1) | ES2935702T3 (es) |
FI (1) | FI3773689T3 (es) |
HR (1) | HRP20230007T1 (es) |
HU (1) | HUE060791T2 (es) |
LT (1) | LT3773689T (es) |
MX (2) | MX2020010701A (es) |
PL (1) | PL3773689T3 (es) |
RS (1) | RS63873B1 (es) |
SI (1) | SI3773689T1 (es) |
WO (1) | WO2019197567A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023501204A (ja) * | 2019-11-15 | 2023-01-18 | エンテローム エスエー | B細胞悪性腫瘍の予防及び治療のための抗原性ペプチド |
CN111197040B (zh) * | 2020-01-21 | 2023-08-08 | 福建亿彤生物科技有限公司 | 壳多糖酶3样蛋白1(chi3l1)抗原表位肽、抗原、抗体、用途及试剂盒 |
WO2023187127A1 (en) * | 2022-03-31 | 2023-10-05 | Enterome S.A. | Antigenic peptides for prevention and treatment of cancer |
IT202200006785A1 (it) * | 2022-04-06 | 2023-10-06 | Istituto Naz Tumori Irccs Fondazione G Pascale | Analoghi di antigeni tumorali da microbiota e usi relativi |
WO2024025397A1 (ko) * | 2022-07-29 | 2024-02-01 | 주식회사 엘지화학 | 항원 전달용 재조합 융합 단백질 및 이의 이용 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
DE68907045T2 (de) | 1989-01-17 | 1993-12-02 | Eniricerche Spa | Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind. |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
US5635363A (en) | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
JP4846906B2 (ja) | 1999-03-19 | 2011-12-28 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
FR2798128B1 (fr) | 1999-09-06 | 2001-11-16 | Inst Nat Sante Rech Med | Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla |
US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
US8569244B2 (en) | 2007-08-20 | 2013-10-29 | Oncotherapy Science, Inc. | FOXM1 peptide and medicinal agent comprising the same |
DK2119726T5 (en) | 2008-05-14 | 2018-03-26 | Immatics Biotechnologies Gmbh | Novel and powerful MHC class II peptides derived from survivin and neurocan |
ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
US9718860B2 (en) | 2009-11-03 | 2017-08-01 | Korea University Research And Business Foundation | Complex of a protein comprising zinc oxide-binding peptides and zinc oxide nanoparticles, and use thereof |
GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
CA2809362C (en) | 2010-08-24 | 2020-03-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Educatn | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
US20140371302A1 (en) | 2011-12-29 | 2014-12-18 | Modema Therapeutics, Inc. | Modified mrnas encoding cell-penetrating polypeptides |
EP2639299A1 (en) | 2012-03-16 | 2013-09-18 | Invectys | Universal cancer peptides derived from telomerase |
AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
PT3536334T (pt) | 2012-05-16 | 2021-09-27 | Stemline Therapeutics Inc | Vacinas contra o cancro dirigidas a células estaminais cancerígenas |
GB201315946D0 (en) | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
SG11201610177UA (en) | 2014-06-06 | 2017-01-27 | Herlev Hospital | Determining antigen recognition through barcoding of mhc multimers |
WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
EP3694541A2 (en) * | 2017-10-09 | 2020-08-19 | Enterome S.A. | Microbiota sequence variants of tumor-related antigenic epitopes |
-
2019
- 2019-04-11 HU HUE19716176A patent/HUE060791T2/hu unknown
- 2019-04-11 DK DK19716176.3T patent/DK3773689T3/da active
- 2019-04-11 MX MX2020010701A patent/MX2020010701A/es unknown
- 2019-04-11 CN CN201980032574.8A patent/CN112118863A/zh active Pending
- 2019-04-11 EP EP22201142.1A patent/EP4169528A1/en active Pending
- 2019-04-11 SI SI201930437T patent/SI3773689T1/sl unknown
- 2019-04-11 HR HRP20230007TT patent/HRP20230007T1/hr unknown
- 2019-04-11 AU AU2019253217A patent/AU2019253217A1/en active Pending
- 2019-04-11 LT LTEPPCT/EP2019/059329T patent/LT3773689T/lt unknown
- 2019-04-11 CA CA3094262A patent/CA3094262A1/en active Pending
- 2019-04-11 FI FIEP19716176.3T patent/FI3773689T3/fi active
- 2019-04-11 EP EP19716176.3A patent/EP3773689B1/en active Active
- 2019-04-11 ES ES19716176T patent/ES2935702T3/es active Active
- 2019-04-11 RS RS20230005A patent/RS63873B1/sr unknown
- 2019-04-11 BR BR112020020780-2A patent/BR112020020780A2/pt unknown
- 2019-04-11 WO PCT/EP2019/059329 patent/WO2019197567A2/en unknown
- 2019-04-11 JP JP2020555892A patent/JP7384819B2/ja active Active
- 2019-04-11 PL PL19716176.3T patent/PL3773689T3/pl unknown
-
2020
- 2020-10-09 MX MX2023014457A patent/MX2023014457A/es unknown
-
2023
- 2023-11-09 JP JP2023191203A patent/JP2024016203A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
HRP20230007T1 (hr) | 2023-03-03 |
BR112020020780A2 (pt) | 2021-03-02 |
ES2935702T3 (es) | 2023-03-09 |
DK3773689T3 (da) | 2023-01-16 |
JP7384819B2 (ja) | 2023-11-21 |
MX2020010701A (es) | 2021-01-20 |
WO2019197567A3 (en) | 2019-11-28 |
FI3773689T3 (fi) | 2023-01-31 |
PL3773689T3 (pl) | 2023-03-13 |
US20210113678A1 (en) | 2021-04-22 |
LT3773689T (lt) | 2023-01-25 |
SI3773689T1 (sl) | 2023-02-28 |
CA3094262A1 (en) | 2019-10-17 |
EP3773689B1 (en) | 2022-11-09 |
CN112118863A (zh) | 2020-12-22 |
EP4169528A1 (en) | 2023-04-26 |
JP2024016203A (ja) | 2024-02-06 |
WO2019197567A2 (en) | 2019-10-17 |
AU2019253217A1 (en) | 2020-10-15 |
HUE060791T2 (hu) | 2023-04-28 |
EP3773689A2 (en) | 2021-02-17 |
JP2021520818A (ja) | 2021-08-26 |
RS63873B1 (sr) | 2023-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023014457A (es) | Peptidos antigenicos para la prevencion y el tratamiento del cancer. | |
MX2022005704A (es) | Peptidos antigenicos para la prevencion y el tratamiento de malignidad de celulas b. | |
PH12020550600A1 (en) | Novel engineered t cell receptors and immune therapy using the same | |
PH12017500484A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers | |
MX2019001769A (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
GB201004575D0 (en) | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers | |
PH12015502638A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
UA103751C2 (ru) | Иммуногенный пептид для иммунотерапии | |
UA103202C2 (ru) | Фармацевтическая композиция опухолеассоциированных пептидов и ее применение для лечения раковых заболеваний | |
EA202091251A2 (ru) | Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка | |
PH12021551208A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
BR112018073221A2 (pt) | métodos de previsão da utilidade de proteínas ou seus fragmentos, métodos de seleção e/ou avaliação de modificações de aminoácidos específicas, método de fornecimento de vacinas e vacina | |
MX355759B (es) | Peptidos topk y vacunas que incluyen los mismos. | |
WO2016011432A3 (en) | Identification of immunogenic mhc class ii peptides for immune-based therapy | |
MX2020011794A (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
MY193910A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
MY194653A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
MY194241A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC | |
MY194244A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc | |
NZ746513A (en) | Novel peptides and combination of peptides for use in immunotherapy against various tumors | |
EA202090821A1 (ru) | Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл |